GDF-15 como Biomarcador em Doenças Cardiovasculares

May, Bruna Miers; Pimentel, Maurício; Zimerman, Leandro Ioschpe; Rohde, Luís Eduardo Paim

doi:10.36660/abc.20200426

Cited by 16 publications

(4 citation statements)

References 56 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients with CAD, a strong association between GDF-15 and CV death and hospitalization for heart failure (HF) has been shown for GDF-15 serum levels above 1.827 ng/L during 3 years of follow-up. 16 Among our study population, the low number of patients with GDF-15 serum levels below this threshold and the short follow-up period may explain the low incidence of cardiovascular events. As future perspective, these preliminary results may suggest a physiopathological rationale for using DPI treatment in the clinical context of myopericardial inflammatory diseases 17 or oxidative stress–based cardiovascular disease.…”

Section: Discussionmentioning

confidence: 85%

Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis

Russo

Fabiani

Leonardi

et al. 2023

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood. Our explorative observational study aimed to evaluate the effect of dual pathway inhibition on plasma inflammation and coagulation markers among real-world patients with CAD and/or PAD. We prospectively included all consecutive patients with an established diagnosis of CAD and/or PAD treated with aspirin 100 mg once daily (OD) and rivaroxaban 2.5 mg twice daily (TD). Clinical evaluation and laboratory analyses, including hemoglobin, renal function (creatinine, urea, and cystatin-C), coagulation markers (INR and aPTT), inflammation markers (IL-6, CRP, lipoprotein-associated phospholipase A2, and copeptin), and growth differentiation factor-15 (GDF-15), were conducted at baseline, before starting treatment, and at 4 and 24 weeks after study drug administration. Fifty-four consecutive patients (mean age 66 6 7 years; male 83%) who completed the 6-month follow-up were included. At 24-week follow-up, a statistically significant reduction in IL-6 serum levels [4.6 (3.5-6.5) vs. 3.4 (2.4-4.3) pg/mL; P = 0.0001] and fibrinogen [336 (290-390) vs. 310 (275-364) mg/dL; P = 0.04] was shown; moreover, a significant increase in GDF-15 serum level [1309 (974-1961) vs. 1538 (1286-2913) pg/mL; P = 0.002] was observed. Hemoglobin, renal function, and cardiovascular homeostasis biomarkers remain stable over the time. The anti-Xa activity at both [0.005 (0-0.02) vs. 0.2 (0.1-0.34); P , 0.0001) significantly increased. The dual pathway inhibitions with low-dose rivaroxaban and aspirin in patients with CAD and/or PAD were associated with the reduction of inflammation biomarkers.

show abstract

Section: Discussionmentioning

confidence: 85%

Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis

Russo

Fabiani

Leonardi

et al. 2023

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

show abstract

“…GDF-15 экспонируется в различных типах клеток в ответ на повреждение ткани, ишемию или стресс. GDF-15 представляет собой маркер воспаления, но также участвует в регуляции клеточного восстановления и клеточного роста [25]. Выявление более высокого уровня GDF-15 для пациентов с ЛГ на фоне патологии левых отделов сердца (группа 2 ЛГ) (Me 2270,97 пг/мл для группы 2 ЛГ vs 1365 пг/мл для пациентов с ЛАГ vs 514 пг/мл для группы контроля) может быть обусловлено выраженным ремоделированием миокарда и гибелью кардиомиоцитов, т.к.…”

Section: биомаркеры крови как детерминанты прогноза биомаркеры сн рем...unclassified

Determinants of prognosis and management of patients with pulmonary hypertension due to left heart disease: a systematic review

2023

View full text Add to dashboard Cite

Patients with pulmonary hypertension (PH) associated with left heart disease usually have a complex comorbidity status and a postcapillary component of PH. The presence and identification of a combined post-/precapillary PH in a cohort of patients with left heart disease is reflected in the more pronounced structural and functional right ventricular changes due to higher pulmonary vascular resistance. Patients with combined post-/ precapillary PH have reduced exercise tolerance and PH phenotype similar to pulmonary arterial hypertension. Detection of combined PH is critical as it may influence the prognosis and management of patients. This review presents modern prognosis markers for patients with PH due to left heart disease, which can be used in clinical practice. The results of randomized clinical trials and pilot studies on the expansion of treatment options in group 2 patients, including the use of PAH-specific agents, were analyzed. The prospects for the treatment of this cohort of patients are discussed.

show abstract

“…8 It is widely known that inflammation plays a major role in atherogenesis; 9 thus, several biomarkers have been studied in this context, such as C-reactive Protein, Interleukin (IL)6, Tumor Necrosis Factor (TNF) alfa, among others. [10][11][12] One of these tools' mean issues is the lack of specificity or its right association with net mortality.…”

mentioning

confidence: 99%